Gleevec holds potential as first drug to successfully treat neurofibromatosis
October 30, 2008Researchers at the Indiana University School of Medicine report that the anti-cancer drug Gleevec holds out promise to become the first effective treatment for neurofibromatosis, a genetic disease that has resisted treatments until now.
The research team is conducting clinical tests of the drug following successful laboratory tests and a "compassionate use" of the drug that showed dramatic results in a three-year-old girl at Riley Hospital for Children in Indianapolis.
Neurofibromatosis results from mutations in a gene called NF1, which causes tumors to form in the cells that make up the protective sheaths around nerves. In humans, NF1 mutations resulting in neurofibromatosis occur in one in 3,500 births, equally affecting both sexes and all races and ethnicities. It is the most common genetic disease in humans that results in a predisposition to cancer.
IU researchers have begun a phase 2 clinical test of Gleevec, treating neurofibromatosis patients with plexiform neurofibromas, which affect about 40 percent of people with neurofibromatosis. Such tumors often have a severe impact on patients' quality of life and can be fatal. They do not respond to chemotherapy drugs and are difficult or impossible to remove surgically.
"We are very hopeful about the potential of this drug and related therapies. There are no other therapies for these tumors. These patients often suffer for years; they sometimes die from these tumors. These are very slow growing tumors that impair people's everyday lives," said D. Wade Clapp, M.D., Freida and Albrecht Kipp Professor of Pediatrics at IU School of Medicine.
The researchers report in the Oct. 31 issue of the journal Cell that the mutated nervous system cells, while still in a pre-tumor state, use molecular signals to recruit inflammatory system cells from the bone marrow to the vicinity of the nerve cells. Those inflammatory system cells – called mast cells – then are put to work helping create the cellular "scaffolding" and blood vessels necessary for the cancerous tumors to form.
The tumorigenic cells use a signaling system protein called c-kit to recruit the mast cells, making Gleevec an attractive treatment candidate because it acts on the c-kit molecule, said the researchers, who include Feng-Chun Yang, M.D., Ph.D., assistant professor of pediatrics, David A. Ingram Jr., M.D., associate professor of pediatrics, and Luis F. Parada, Ph.D., professor of developmental biology at the University of Texas Southwestern Medical Center.
The researchers discovered that while both copies of the NF1 gene in the nervous system cells must be mutated in order for tumors to form, those mutations alone are not sufficient. Tumor growth is enabled by additional NF1 mutations in nearby cells – most likely the mast cells. However, unlike the nerve cells, where both NF1 genes are mutated, only one of the mast cell NF1 genes needs to be mutated for tumor growth to begin.
While the research was being conducted in animal models, a critically ill three-year-old patient presented at Riley Hospital for Children with a plexiform neurofibroma that was compressing her airway. With Gleevec administered under a compassionate use protocol, the patient's tumor was reduced by about 80 percent, Dr. Clapp said. The patient was subsequently removed from treatment and is being followed, he said.
Because Gleevec is already an FDA- approved drug used to treat chronic myeloid leukemia and several other types of cancer, the human testing for NF1 will not need to begin with safety testing.
"Patients taking Gleevec for chronic myeloid leukemia have often been taking it for 10 to 15 years without major consequences, and live a normal life. It's a very good, very well tolerated drug," Dr. Clapp said.
Researchers expect to enroll about 40 patients, ranging from age three to adults, in the clinical trial.
Source: Indiana University
-
New drug extends survival in patients with drug-resistant prostate cancer
Feb 01, 2012 |
5 / 5 (1) |
0
-
The past, present and future of cancer
Mar 18, 2011 |
not rated yet |
0
-
Study points to liver, not brain, as origin of Alzheimer's plaques
Mar 03, 2011 |
4.8 / 5 (13) |
2
-
Scientists discover cell of origin for childhood muscle cancer
Feb 15, 2011 |
1 / 5 (1) |
0
-
Protein that drives survival of gastrointestinal tumors identified
Dec 23, 2010 |
4.7 / 5 (3) |
0
-
Engineers build first sub-10-nm carbon nanotube transistor
Feb 01, 2012 |
4.9 / 5 (33) |
30
-
Something old, something new: Evolution and the structural divergence of duplicate genes
Jan 31, 2012 |
4.6 / 5 (7) |
1
-
The hidden nanoworld of ice crystals: Revealing the dynamic behavior of quasi-liquid layers
Jan 30, 2012 |
5 / 5 (4) |
1
-
Stock market network reveals investor clustering
Jan 27, 2012 |
3.9 / 5 (23) |
8
-
Of microchemistry and molecules: Electronic microfluidic device synthesizes biocompatible probes
Jan 26, 2012 |
5 / 5 (2) |
0
-
Is Everyday Technology Killing Us?
Feb 08, 2012
-
Exercise and weight loss
Feb 08, 2012
-
Why do we have head aches? Our brains can't feel anything.
Feb 07, 2012
-
"The end of diseases" by David Agus, interview from Daily Show with Jon Stewart
Feb 04, 2012
-
Oncolytic adenovirus
Feb 04, 2012
-
Nutrition label stuffs and diets
Feb 02, 2012
- More from Physics Forums - Medical Sciences
More news stories
Botox developer rues missing out on billions
Botox developer Alan Scott says he rues the day he handed over rights to the best-selling wrinkle-smoothing drug to a US company for just $4.5 million, saying he might have become a billionaire.
Medicine & Health / Medications
2 minutes ago |
not rated yet |
0
Starve a virus, feed a cure? Findings show how some cells protect themselves against HIV
A protein that protects some of our immune cells from the most common and virulent form of HIV works by starving the virus of the molecular building blocks that it needs to replicate, according to research published online ...
14 hours ago |
5 / 5 (3) |
0
|
Overeating may double risk of memory loss
New research suggests that consuming between 2,100 and 6,000 calories per day may double the risk of memory loss, or mild cognitive impairment (MCI), among people age 70 and older. The study was released today and will be ...
Medicine & Health / Neuroscience
10 hours ago |
5 / 5 (2) |
0
|
Declining health-care productivity in England: Who says so?
Reports that the National Health Service in England has been declining in productivity in the last decade appear to have been accepted as fact. However, a Viewpoint published Online First by The Lancet disputes this. The Vi ...
8 hours ago |
1 / 5 (1) |
1
Injured boomers beware: Know when to see doctor
(AP) -- It happened to nurse Jane Byron years after an in-line skating fall, business owner Haralee Weintraub while doing "men's" push-ups, and avid cyclist Gene Wilberg while lifting a heavy box.
15 hours ago |
5 / 5 (1) |
0
Japan's Fukushima reactor may be reheating: operator
Temperature readings at one of the crippled Fukushima nuclear reactors have risen above Japan's stringent new safety standard but there was no immediate danger, its operator said Sunday.
Australian women reject 'I love u' texts
Australian women may have embraced the digital era, but they prefer a face-to-face declaration of affection to an "I love u" text and find men addicted to their mobile phones a major turnoff.
Scientists discover molecular secrets of 2,000-year-old Chinese herbal remedy
For roughly two thousand years, Chinese herbalists have treated Malaria using a root extract, commonly known as Chang Shan, from a type of hydrangea that grows in Tibet and Nepal. More recent studies suggest that halofuginone, ...
New method to examine batteries -- MRI from the inside
There is an ever-increasing need for advanced batteries for portable electronics, such as phones, cameras, and music players, but also to power electric vehicles and to facilitate the distribution and storage of energy derived ...
Google might launch Drive for cloud storage soon
(PhysOrg.com) -- Google's next big move, according to the Wall Street Journal, is a cloud storage service called Drive. Hardly first to the plate, Google is simply catching up to introducing its cloud reposi ...
A mitosis mystery solved: How chromosomes align perfectly in a dividing cell
Although the process of mitotic cell division has been studied intensely for more than 50 years, Whitehead Institute researchers have only now solved the mystery of how cells correctly align their chromosomes during symmetric ...